| Literature DB >> 36011941 |
Israel Guardado-Luevanos1, Ronell Bologna-Molina2,3, José Sergio Zepeda-Nuño4, Mario Isiordia-Espinoza5, Nelly Molina-Frechero6, Rogelio González-González3, Mauricio Pérez-Pérez7, Sandra López-Verdín8.
Abstract
Introduction: Knowledge of the oral manifestations associated with SARS-CoV-2 infection, the new coronavirus causing the COVID-19 pandemic, was hindered due to the restrictions issued to avoid proximity between people and to stop the rapid spread of the disease, which ultimately results in a hyperinflammatory cytokine storm that can cause death. Because periodontal disease is one of the most frequent inflammatory diseases of the oral cavity, various theories have emerged postulating periodontal disease as a risk factor for developing severe complications associated with COVID-19. This motivated various studies to integrate questions related to periodontal status. For the present work, we used a previously validated self-report, which is a useful tool for facilitating epidemiological studies of periodontal disease on a large scale. Methodology: A blinded case-control study with participants matched 1:1 by mean age (37.7 years), sex, tobacco habits and diseases was conducted. After the diagnostic samples for SARS-CoV-2 detection were taken in an ad hoc location at Guadalajara University, the subjects were interviewed using structured questionnaires to gather demographic, epidemiological and COVID-19 symptom information. The self-reported periodontal disease (Self-RPD) questionnaire included six questions, and subjects who met the criteria with a score ≥ 2 were considered to have periodontal disease.Entities:
Keywords: COVID-19; SARS-CoV-2; case-control studies; periodontal disease; self-report
Mesh:
Year: 2022 PMID: 36011941 PMCID: PMC9407774 DOI: 10.3390/ijerph191610306
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Case-control descriptive data and p values.
| Controls (n = 117) | Cases (n = 117) | ||
|---|---|---|---|
|
| |||
|
| 37.7 ± 13.2, 17–67 years. | 37.7 ± 12.5, 17–66 years. | 1.00 |
|
| |||
| Female | 69 (59) | 69 (59) | 1.00 |
| Male | 48 (41) | 48 (41) | |
|
| |||
| Yes | 30 (25.6) | 30 (25.6) | 1.00 |
| No | 87 (74.4) | 87(74.4) | |
|
| |||
| Yes | 22 (18.8) | 22 (18.8) | 1.00 |
| No | 95 (81.2) | 95 (81.2) | |
|
| |||
|
| |||
| Yes | 39 (33.3) | 61 (52.1) | 0.00 * |
| No | 78 (66.7) | 56 (47.9) | |
|
| |||
| Fever | 58 (51.3) | 59 (51.3) | 1.00 |
| Dry cough | 71 (67) | 76 (68.5) | 0.88 |
| Nasal congestion | 19 (19.4) | 24 (24.2) | 0.01 |
| Tiredness | 57 (54.3) | 73 (64) | 0.16 |
| Coughing up phlegm | 14 (14.4) | 15 (15.2) | 1.00 |
| Shortness of breath | 17 (17.5) | 15 (15) | 0.70 |
| Cut Body | 43 (42.6) | 35 (33.7) | 0.19 |
| Headache | 78 (70.9) | 98 (82.5) | 0.01* |
| Chills | 34 (34.0) | 35 (33.3) | 1.00 |
| Muscle pain | 44 (43.1) | 51 (46.8) | 0.67 |
| Joint pain | 29 (29.6) | 40 (37.4) | 0.30 |
| Runny nose | 34 (33.3) | 35 (33.3) | 1.00 |
| Burning throat | 53 (50.5) | 57 (53.3) | 0.39 |
| Flu | 30 (30.3) | 48 (46.2) | 0.02 * |
| Conjunctivitis | 17 (17.5) | 33 (32.0) | 0.02 * |
| Diarrhea | 22 (22.4) | 27 (26.0) | 0.62 |
| Vomit | 13 (13.5) | 7 (7.1) | 0.16 |
| Stomach ache | 18 (18.6) | 11 (11.1) | 0.16 |
| Fast breathing | 8 (8.6) | 5 (5.2) | 0.39 |
| Convulsions | 1 (1.1) | 1 (1.0) | 1.00 |
| Olfactory disturbance | 35 (35.0) | 59 (57.8) | 0.00 * |
| Gustatory disturbance | 32 (32.3) | 51 (49.0) | 0.01 * |
Frequencies were based solely on participants included for match purposes. Cases: Positive for SARS-CoV-2; Controls: Negative for SARS-CoV-2, χ2 test, * p < 0.05, 95% CI.
Questions of self-reported periodontal disease differences between cases and control: descriptive data and p values.
| Controls | Cases | ||||
|---|---|---|---|---|---|
| n | % | n | % | ||
|
| |||||
| Yes | 42 | 35.9 | 56 | 47.9 | 0.08 |
| No | 75 | 64.1 | 61 | 52.1 | |
|
| |||||
| Yes | 16 | 13.7 | 22 | 18.8 | 0.37 |
| No | 101 | 86.3 | 95 | 81.2 | |
|
| |||||
| Yes | 31 | 26.5 | 32 | 27.4 | 1.00 |
| No | 86 | 73.5 | 85 | 72.6 | |
|
| |||||
| Yes | 9 | 7.7 | 5 | 4.3 | 0.40 |
| No | 108 | 92.3 | 112 | 95.7 | |
|
| |||||
| Yes | 49 | 41.9 | 64 | 54.7 | 0.06 |
| No | 68 | 58.1 | 53 | 45.3 | |
|
| |||||
| Yes | 7 | 6.0 | 6 | 5.0 | 0.50 |
| No | 110 | 94.0 | 111 | 95.0 | |
Figure 1Self-RPD between the case and control groups. Control self-RPD positive (+): n = 66, 54.4%; Control self-RPD negative (−): n = 51,43.6%, Cases self-RPD positive (+): n = 95, 81.2%; Cases self-RPD negative (−).: n = 22, 18.8%. Statistics: χ2 test. Abbreviations and symbols: Self-RPD: Self-reported periodontitis disease, * p value < 0.001.
Figure 2Self-RPD and the number of symptoms between groups. Control self-RPD positive (+): median = 7.0, Q1 = 4.7, Q3 = 9.0, minimum = 0.0, maximum = 14.0; Control self-RPD negative (−): median = 6.0, Q1 = 4.0, Q3 = 8.0, minimum = 0.0, maximum = 16.0; Case self-RPD positive (+): median = 8.0, Q1 = 6.0, Q3 = 10.0, minimum = 2.0, maximum = 19.0; Case self-RPD negative (−): median= 6.0, Q1 = 5.0, Q3 = 7.0, minimum = 0.0, maximum = 13.0. Statistics: Mann–Whitney U. Abbreviations and symbols: Self-RPD: Self-reported periodontitis disease, NS: Not significant, * p value < 0.01, ** p value < 0.05.